MET and EGFR mutations identified in ALK-rearranged pulmonary adenocarcinoma: Molecular analysis of 25 ALK-positive cases

Journal of Thoracic Oncology

Volumn 8, Issue 5, 2013, Pages 574-581

  Boland, Jennifer M ^a   Jang, Jin Sung ^a   Li, Jun ^a,c   Lee, Adam M ^b   Wampfler, Jason A ^a   Erickson Johnson, Michele R ^a   Soares, Ibere ^a   Yang, Ping ^a   Jen, Jin ^a   Oliveira, Andre M ^a   Yi, Eunhee S ^a  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c CHINA JAPAN UNION HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

Adenocarcinoma; ALK; EGFR; MET

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; B RAF KINASE; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; JANUS KINASE 2; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE B BETA; SCATTER FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COPY NUMBER VARIATION; ENZYME ACTIVITY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENE REARRANGEMENT; GENE SEQUENCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; MALE; MUTATION RATE; ONCOGENE; PRIORITY JOURNAL; PROTEIN ANALYSIS;

EID: 84876412641     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318287c395     Document Type: Article

References (42)

1. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 2008;3:13-17.
2. Soda M, Choi YL, Enomoto M, et al. Identifcation of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-566.
3. Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009;15:5216-5223.
4. Soda M, Takada S, Takeuchi K, et al. A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci USA 2008;105:19893-19897.
5. Zhang X, Zhang S, Yang X, et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer 2010;9:188.
6. Yang P, Kulig K, Boland JM, et al. Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma. J Thorac Oncol 2012;7:90-97.
7. Boland JM, Erdogan S, Vasmatzis G, et al. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and tran-scriptional up-regulation in non-small cell lung carcinomas. Hum Pathol 2009;40:1152-1158.
8. Yoshida A, Tsuta K, Nakamura H, et al. Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol 2011;35:1226-1234.
9. Yoshida A, Tsuta K, Watanabe S, et al. Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component. Lung Cancer 2011;72:309-315.
10. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-1703.
11. Administration U.F.a.D. FDA approves Xalkori with companion diagnostic for a type of late-stage lung cancer 08-26-2011. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm269856.htm.
12. Koivunen J P, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and effcacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008;14:4275-4283.
13. Zhu CQ, da Cunha Santos G, Ding K, et al.; National Cancer Institute of Canada Clinical Trials Group Study BR.21. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008;26:4268-4275.
14. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to geftinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306-13311.
15. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to geftinib. N Engl J Med 2004;350:2129-2139.
16. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to geftinib therapy. Science 2004;304:1497-1500.
17. Kim HR, Shim HS, Chung JH, et al. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Cancer 2012;118:729-739.
18. Xu J, He J, Yang H, et al. Somatic mutation analysis of EGFR, KRAS, BRAF and PIK3CA in 861 patients with non-small cell lung cancer. Cancer Biomark 2011;10:63-69.
19. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to geftinib or erlotinib. PLoS Med 2005;2:e17.
20. Mao C, Qiu LX, Liao RY, et al. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analy-sis of 22 studies. Lung Cancer 2010;69:272-278.
21. Tiseo M, Gelsomino F, Boggiani D, et al. EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations. Lung Cancer 2011;71:241-243.
22. Popat S, Vieira de Araújo A, Min T, et al. Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib. J Thorac Oncol 2011;6:1962-1963.
23. Kuo Y W, Wu SG, Ho CC, Shih JY. Good response to geftinib in lung ade-nocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation. J Thorac Oncol 2010;5:2039-2040.
24. Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012;18:1472-1482.
25. Ladanyi M, Pao W. Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod Pathol 2008;21:S16-S22.
26. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histo-logical evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3:75ra26.
27. Zhang S, Wang F, Keats J, et al. Crizotinib-resistant mutants of EML4-ALK identifed through an accelerated mutagenesis screen. Chem Biol Drug Des 2011;78:999-1005.
28. Katayama R, Shaw AT, Khan TM, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med 2012;4:120ra17.
29. Yi ES, Boland JM, Maleszewski JJ, et al. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol 2011;6:459-465.
30. Thomas RK, Baker AC, Debiasi RM, et al. High-throughput oncogene mutation profling in human cancer. Nat Genet 2007;39:347-351.
31. Choi YL, Takeuchi K, Soda M, et al. Identifcation of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res 2008;68:4971-4976.
32. Shinmura K, Kageyama S, Igarashi H, et al. EML4-ALK fusion transcripts in immunohistochemically ALK-positive non-small cell lung carcinomas. Exp Ther Med 2010;1:271-275.
33. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to geftinib. N Engl J Med 2005;352:786-792.
34. Yi ES, Chung JH, Kulig K, Kerr KM. Detection of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer and related issues in ALK inhibitor therapy: a literature review. Mol Diagn Ther 2012;16:143-150.
35. Okuda K, Sasaki H, Yukiue H, Yano M, Fujii Y. Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer. Cancer Sci 2008;99:2280-2285.
36. Tsuta K, Kozu Y, Mimae T, et al. c-MET/phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomas. J Thorac Oncol 2012;7:331-339.
37. Dziadziuszko R, Wynes M W, Singh S, et al. Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer. J Thorac Oncol 2012;7:340-347.
38. Krishnaswamy S, Kanteti R, Duke-Cohan JS, et al. Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res 2009;15:5714-5723.
39. Ma PC, Kijima T, Maulik G, et al. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cyto-skeletal functions. Cancer Res 2003;63:6272-6281.
40. Tengs T, Lee JC, Paez JG, et al. A transforming MET mutation discovered in non-small cell lung cancer using microarray-based resequencing. Cancer Lett 2006;239:227-233.
41. Jagadeeswaran R, Jagadeeswaran S, Bindokas V P, Salgia R. Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells. Am J Physiol Lung Cell Mol Physiol 2007;292:L1488-L1494.
42. Christensen JG, Zou HY, Arango ME, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007;6:3314-3322.